

=> s 13

L4 2 L3

=> d abs bib fhitstr 1-2

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN  
GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. [I; X = CHR2, CHR2A; A = (un)substituted alkylene, alkenylene; Y = a bond, C(:O), C(:S), SO2, COO, CONH and derivs., etc.; R1, R' = independently H, (un)substituted alk(en)yl, aryl, etc.; RA, RB = independently H, halo, alk(en)yl, alkoxy, alkylthio, NH2 and derivs.; or RACCRB = (un)substituted fused hetero/aryl, fused 5- to 7-membered saturated ring; R'' = H, non-interfering substituent; and their pharmaceutically acceptable salts], were prepared as immunomodulators for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases. For example, reacting 1-[3-(aminooxy)propyl]-2-propyl-1H-imidazo[4,5-c]quinolin-4-amine (preparation given) with cyclopropanecarbonyl chloride gave title compound II (m.p. = 103-105°). Thus, induced interferon and tumor necrosis factor in human cells (no data).

AN 2005:177837 CAPLUS

DN 142:280205

TI Preparation of hydroxylamine substituted imidazo-containing compounds as inducers of cytokine biosynthesis for treatment of viral and neoplastic disease

IN Kshirsagar, Tushar A.; Amos, David T.; Dellaria, Joseph F., Jr.; Heppner, Philip D.; Langer, Scott E.; Zimmermann, Bernhard M.

PA 3M Innovative Properties Company, USA

SO PCT Int. Appl., 254 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2005018556	A2	20050303	WO 2004-US26158	20040812
	WO 2005018556	A3	20050929		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004266658	A1	20050303	AU 2004-266658	20040812

CA 2535120	A1	20050303	CA 2004-2535120	20040812
EP 1653955	A2	20060510	EP 2004-780922	20040812
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1835750	A	20060920	CN 2004-80023051	20040812
BR 2004013558	A	20061017	BR 2004-13558	20040812
JP 2007502293	T	20070208	JP 2006-523371	20040812
US 20080114019	A1	20080515	US 2006-595058	20060123
MX 2006001674	A	20060512	MX 2006-1674	20060210
PRAI US 2003-494605P	P	20030812		
US 2003-494608P	P	20030812		
WO 2004-US26158	W	20040812		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 142:280205; MARPAT 142:280205


IT 1044643-63-1

RL: PRPH (Prophetic)

(Preparation of hydroxylamine substituted imidazo-containing compounds as inducers of cytokine biosynthesis for treatment of viral and neoplastic disease)

RN 1044643-63-1 CAPLUS

CN Cyclopropanecarboxamide, N-[4-[4-amino-2-(ethoxymethyl)-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-1-yl]butoxy]- (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN  
GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. [I; X = CHR2A; A = alkylene, alkenylene optionally interrupted by one or more O; R1, R' = independently H, (un)substituted

alk(en)yl, hetero/aryl, hetero/arylalkylenyl, heterocyclyl, heterocyclylalkylenyl, etc.; RA, RB = independently H, halo, alk(en)yl, alkoxy, alkylthio, NH<sub>2</sub> and derivs.; or RACCRB = (un)substituted fused hetero/aryl, fused 5- to 7-membered saturated ring; R'' = H, non-interfering substituent; and their pharmaceutically acceptable salts], were prepared as immunomodulators for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases. Thus, reacting 4-fluorobenzaldehyde with 1-[3-(aminooxy)propyl]-2-propyl-1H-imidazo[4,5-c]quinolin-4-amine (preparation given) in MeOH gave oxime II. I induced interferon and tumor necrosis factor in human cells (no data).

AN 2005:177833 CAPLUS

DN 142:280204

TI Preparation of oxime substituted imidazo-containing compounds as inducers of cytokine biosynthesis for treatment of viral and neoplastic disease

IN Kshirsagar, Tushar; Amos, David T.; Dellaria, Joseph F., Jr.; Heppner, Philip D.; Langer, Scott E.; Zimmermann, Bernhard M.

PA 3M Innovative Properties Company, USA

SO PCT Int. Appl., 348 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005018551	A2	20050303	WO 2004-US26065	20040812
	WO 2005018551	A3	20060511		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2004266641	A1	20050303	AU 2004-266641	20040812
	CA 2535117	A1	20050303	CA 2004-2535117	20040812
	EP 1653914	A2	20060510	EP 2004-780839	20040812
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
	BR 2004012902	A	20060926	BR 2004-12902	20040812
	JP 2007502288	T	20070208	JP 2006-523340	20040812
	CN 101094670	A	20071226	CN 2004-80023366	20040812
	US 20070066639	A1	20070322	US 2006-595065	20060126
	MX 2006001669	A	20060428	MX 2006-1669	20060210
	IN 2006CN00516	A	20070622	IN 2006-CN516	20060210
PRAI	US 2003-494605P	P	20030812		
	US 2003-494608P	P	20030812		
	WO 2004-US26065	W	20040812		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 142:280204; MARPAT 142:280204


IT 1044345-64-3

RL: PRPH (Prophetic)

(Preparation of oxime substituted imidazo-containing compounds as inducers of cytokine biosynthesis for treatment of viral and neoplastic disease)

RN 1044345-64-3 CAPLUS

CN Formaldehyde, O-[3-[4-amino-7-(3-pyridinyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl]oxime (CA INDEX NAME)



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)  
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT